RxDoctor Payments Data

Zahid Saqib, MD

Family Medicine · Evansville, INNPI 1710063292

Payments from drug & device makers

$1,556in general payments, 2019–2025

Across 98 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$229
  • Merck$207
  • Sanofi-aventis U.S. LLC$174
  • GSK$173
  • Avanir Pharmaceuticals, Inc.$163
  • Novartis$136
  • plus $475 from 11 others

What the payments were for

  • Food & beverage$1,54599%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,556 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$125,276
Medicare patients
253
Services billed
21,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab24$179,726
EliquisApixaban256$98,363
Invega SustennaPaliperidone Palmitate21$77,534
NuplazidPimavanserin Tartrate28$70,683
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$59,408
XareltoRivaroxaban111$41,130
Soliqua 100-33Insulin Glargine/Lixisenatide17$24,036
RexultiBrexpiprazole25$23,046
JardianceEmpagliflozin68$19,895
FarxigaDapagliflozin Propanediol50$19,427
OzempicSemaglutide14$16,298
Glatiramer Acetate11$15,276
AptiomEslicarbazepine Acetate25$15,260
Breo ElliptaFluticasone/Vilanterol35$14,243
MyrbetriqMirabegron44$14,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$35$118,664132 claims
PfizerEliquis, Abrysvo$123$104,017274 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$173$79,627138 claims
AstraZenecaFarxiga, Breztri Aerosphere$229$31,76968 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$174$24,03617 claims
Otsuka America Pharmaceutical, Inc.Rexulti$56$23,04625 claims
MerckJanuvia, Janumet Xr$207$15,75950 claims
Sunovion Pharmaceuticals Inc.Aptiom$26$15,26025 claims
Astellas Pharma US IncMyrbetriq$11$14,19544 claims
NovartisEntresto$136$9,66029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →